sibutramine
Trade name: meridia
Approved
Nov 22, 1997
Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. It works as a serotonin–norepinephrine reuptake inhibitor (SNRI) similar to certain antidepressants. Until 2010, it was widely marketed and prescribed as an adjunct in the treatment of obesity along with diet and exercise. It has been associated with increased cardiovascular diseases and strokes and has been withdrawn from the market in 2010 in several countries and regions including Australia, Canada, China, the European Union, Hong Kong, India, Mexico, New Zealand, the Philippines, Thailand, the United Kingdom, and the United States. It was never approved in Japan. However, the drug remains available in some countries. — Wikipedia
Clinical trial activity
31 trials · 28 clinical orgs · 1 marketing orgs
Earliest trial started Sep 1, 1998 (NCT00645255)
Timeline
Indications
Approved for
Mechanism of action
Approval history
- approvedNov 22, 1997
Chemistry & pharmacology
SMILES
CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1.Cl.O- Mol. weight
- 334.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989830 ↗
- WikipediaSibutramine ↗
- NCATS9GG866ZP1E ↗
- ChEMBLCHEMBL1419 ↗
- ChEMBLCHEMBL1200765 ↗
Also known as
- bts 54524
- bts 54524
- bts 54 524
- bts-54524
- bts-54524
- bts-54524
- butramin
- butramin
- didemethyl sibutramine hcl
- didemethyl sibutramine hydrochloride
- didesmethylsibutramine
- didesmethylsibutramine
- di-desmethylsibutramine
- meredia
- meridia
- meridia
- meridia
- mono-desmethylsibutramine
- n-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-n,n-dimethylamine hcl
- racemic sibutramine
- (r)-ddms
- reductil
- reductil
- reductil
- sibutramina
- sibutramina
- sibutramine
- sibutramine
- sibutramine
- sibutramine
- sibutramine
- sibutramine
- sibutramine
- sibutramine
- sibutramine
- sibutramine
- sibutramine
- (+/-)-sibutramine
- sibutramine hcl
- sibutramine hcl
- sibutramine hcl
- sibutramine hydrochloride
- sibutramine hydrochloride
- sibutramine hydrochloride
- sibutramine hydrochloride
- sibutramine hydrochloride
- sibutramine hydrochloride hydrate
- sibutramine hydrochloride monohydrate
- sibutraminum
- sibutraminum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05209984 | Phase 3 | Jun 30, 2024 | Eurofarma Laboratorios S.A. |
| NCT05821543 | Phase 4 | Jul 3, 2020 | Pirogov Russian National Research Medical University, Promomed, LLC |
| NCT01184560 | N/A | Feb 1, 2010 | Gachon University |
| NCT00993421 | Phase 2 | Oct 1, 2009 | Eli Lilly |
| NCT00914212 | Phase 1 | May 1, 2009 | Merck |
| NCT01170364 | N/A | Feb 1, 2009 | AstraZeneca, Columbia University |
| NCT00829283 | N/A | Nov 1, 2008 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Yale University |
| NCT00941382 | Phase 3 | Nov 1, 2008 | Laboratorios Silanes S.A. de C.V., University of Guadalajara |
| NCT01421706 | Phase 1 | Jul 1, 2008 | Inje University |
| NCT01597609 | Phase 1 | May 1, 2008 | GlaxoSmithKline |
| NCT00537420 | Phase 2 | Oct 1, 2007 | mdRNA |
| NCT00537810 | Phase 4 | Sep 1, 2007 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Yale University |
| NCT00402077 | Phase 2 | Nov 1, 2006 | Amylin, AstraZeneca |
| NCT00433641 | Phase 4 | Jul 1, 2006 | Mayo Clinic, National Institutes of Health (NIH) |
| NCT00212173 | N/A | Sep 13, 2005 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Pennsylvania |
| NCT00115063 | Phase 4 | Jul 1, 2005 | Louisiana Office of Group Benefits, University of Vermont |
| NCT00134199 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2005 | Pfizer |
| NCT00330525 | Phase 2 | Jan 1, 2005 | Mayo Clinic |
| NCT00165685 | Phase 3 | Jul 1, 2004 | Eisai |
| NCT00234988 | Phase 4 | Jun 1, 2004 | Abbott |
Organizations
Research & Development (28)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 7 | 7 | 2 | 1998 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 3 | 1 | 2 | 2005 |
| Aristotle University of Thessaloniki | Academic/Hospital | 2 | 2 | 1 | 2004 |
| AstraZeneca | For profit | 2 | 1 | 2 | 2006 |
| Eli Lilly | For profit | 2 | 2 | 2 | 2001 |
| Mayo Clinic | Academic/Hospital | 2 | 2 | 2 | 2005 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2006 |
| Yale University | Academic/Hospital | 2 | 2 | 2 | 2007 |
| Amylin | For profit | 1 | 0 | 1 | 2006 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Eisai | For profit | 1 | 1 | 1 | 2004 |
| Eurofarma Laboratorios S.A. | For profit | 1 | 1 | 1 | 2024 |
| Gachon University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2008 |
| Inje University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Laboratorios Silanes S.A. de C.V. | For profit | 1 | 1 | 1 | 2008 |
| Laval University | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Louisiana Office of Group Benefits | Academic/Hospital | 1 | 0 | 1 | 2005 |
| mdRNA | For profit | 1 | 1 | 1 | 2007 |
| Merck | For profit | 1 | 1 | 1 | 2009 |